Efficacy of Piperacillin Combined with the Penem β-Lactamase Inhibitor BLI-489 in Murine Models of Systemic Infection | Zendy

Peter J. Petersen | Zendy; C. Hal Jones | Zendy; Aranapakam M. Venkatesan | Zendy; Patricia A. Bradford | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy of Piperacillin Combined with the Penem β-Lactamase Inhibitor BLI-489 in Murine Models of Systemic Infection

Author(s) -

Peter J. Petersen,

C. Hal Jones,

Aranapakam M. Venkatesan,

Patricia A. Bradford

Publication year - 2009

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01549-08

Subject(s) - piperacillin , medicine , microbiology and biotechnology , antibiotics , beta lactamase inhibitors , antibacterial agent , pharmacology , biology , bacteria , pseudomonas aeruginosa , genetics

The in vivo efficacy of piperacillin in combination with the penem inhibitor BLI-489 was determined using acute lethal systemic infections in mice. On the basis of preliminary results with various ratios, a dosing ratio of 8:1 was found to be optimal for retention of enhanced efficacy. Piperacillin-BLI-489 dosed at an 8:1 ratio was efficacious against murine infections caused by class A (including extended-spectrum beta-lactamases), class C (AmpC), and class D beta-lactamase-expressing pathogens.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research